Bulgaria added to the expansive list of countries
Black Swan Analysis are delighted to announce that Bulgaria becomes the latest country to be incorporated into the Rx Price Index™ database. With roughly 140,000 unique records, pharmaceutical pricing information from Bulgarian markets can be easily found dating from June 2015 to present. The platform now boasts 27 EU countries as well as the recent inclusion of the USA. With the planned addition of Japanese market data before the end of 2019, the platform represents a global coverage of prescription-only medicine pricing information.
What can Rx Price Index™ do for you?
The Rx platform contains pricing information from European and international countries for all prescription-only medicines available. Four price points are calculated for each product, working back from a retail price to ex-manufacturer price, using our external and internal validation methods. Data is compiled from reputable and verified sources such as government and health authorities. All information covering the products are translated and converted into a standardised format, making the data output as clear as possible. With a broad range of EU and international countries, Rx gives you a comprehensive picture of the competitive landscape. Market price points allow for an optimal product launch sequence, as well as being able to utilise a transparent pricing strategy.
RxPriceIndex™ delivers powerful insights and up to date pharmaceutical pricing data so you can understand the pricing landscape by seamlessly searching for and comparing pharmaceutical products across global markets. Speak to our experts to find out more.